miR-19a contributes to gefitinib resistance and epithelial mesenchymal transition in non-small cell lung cancer cells by targeting c-Met

Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is used as a first-line treatment for advanced non-small cell lung cancer (NSCLC). However, most NSCLC patients inevitably develop gefitinib resistance, and the mechanisms underlying this resistance are not fully unders...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Xiaonian, Lai, Senyan, Hu, Fayong, Li, Guodong, Wang, Guihua, Luo, Xuelai, Fu, Xiangning, Hu, Junbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462753/
https://www.ncbi.nlm.nih.gov/pubmed/28592790
http://dx.doi.org/10.1038/s41598-017-01153-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462753/
https://www.ncbi.nlm.nih.gov/pubmed/28592790
http://dx.doi.org/10.1038/s41598-017-01153-0

Ejemplares similares